1
|
Hong X, Xu Y, Pang SW. Effects of Confined Microenvironments with Protein Coating, Nanotopography, and TGF-β Inhibitor on Nasopharyngeal Carcinoma Cell Migration through Channels. J Funct Biomater 2024; 15:263. [PMID: 39330238 PMCID: PMC11433299 DOI: 10.3390/jfb15090263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2024] [Revised: 09/03/2024] [Accepted: 09/08/2024] [Indexed: 09/28/2024] Open
Abstract
Distant metastasis is the primary cause of unsuccessful treatment in nasopharyngeal carcinoma (NPC), suggesting the crucial need to comprehend this process. A tumor related to NPC does not have flat surfaces, but consists of confined microenvironments, proteins, and surface topography. To mimic the complex microenvironment, three-dimensional platforms with microwells and connecting channels were designed and developed with a fibronectin (FN) coating or nanohole topography. The potential of the transforming growth factor-β (TGF-β) inhibitor (galunisertib) for treating NPC was also investigated using the proposed platform. Our results demonstrated an increased traversing probability of NPC43 cells through channels with an FN coating, which correlated with enhanced cell motility and dispersion. Conversely, the presence of nanohole topography patterned on the platform bottom and the TGF-β inhibitor led to a reduced cell traversing probability and decreased cell motility, likely due to the decrease in the F-actin concentration in NPC43 cells. This study highlights the significant impact of confinement levels, surface proteins, nanotopography, and the TGF-β inhibitor on the metastatic probability of cancer cells, providing valuable insights for the development of novel treatment therapies for NPC. The developed platforms proved to be useful tools for evaluating the metastatic potential of cells and are applicable for drug screening.
Collapse
Affiliation(s)
- Xiao Hong
- Department of Electrical Engineering, City University of Hong Kong, Hong Kong, China; (X.H.); (Y.X.)
- Centre for Biosystems, Neuroscience, and Nanotechnology, City University of Hong Kong, Hong Kong, China
| | - Yuanhao Xu
- Department of Electrical Engineering, City University of Hong Kong, Hong Kong, China; (X.H.); (Y.X.)
- Centre for Biosystems, Neuroscience, and Nanotechnology, City University of Hong Kong, Hong Kong, China
| | - Stella W. Pang
- Department of Electrical Engineering, City University of Hong Kong, Hong Kong, China; (X.H.); (Y.X.)
- Centre for Biosystems, Neuroscience, and Nanotechnology, City University of Hong Kong, Hong Kong, China
| |
Collapse
|
2
|
S M N Mydin RB, Azlan A, Okekpa SI, Gooderham NJ. Regulatory role of miRNAs in nasopharyngeal cancer involving PTEN/PI3K/AKT, TGFβ/SMAD, RAS/MAPK, Wnt/β-catenin and pRB-E2F signaling pathways: A review. Cell Biochem Funct 2024; 42:e3945. [PMID: 38362935 DOI: 10.1002/cbf.3945] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Revised: 01/15/2024] [Accepted: 01/17/2024] [Indexed: 02/17/2024]
Abstract
MicroRNAs (miRNA) are small and conserved noncoding RNA molecules that regulate gene expression at the posttranscriptional level. These groups of RNAs are crucial in various cellular processes, especially in mediating disease pathogenesis, particularly cancer. The dysregulation of miRNAs was reported in many cancer types, including nasopharyngeal cancer (NPC), which is a malignant tumor of the nasopharynx. In this review, miRNAs involvement in crucial signaling pathways associated with NPC such as PTEN/PI3K/AKT, TGFβ/SMAD, RAS/MAPK, Wnt/β-catenin and pRB-E2F was investigated. miRNAs could function as tumor suppressor-miR or onco-miR in NPC profoundly influenced cell cycle, apoptosis, proliferation, migration, and metastasis. This comprehensive review of current literature provided a thorough profile of miRNAs and their interplay with the aforementioned signaling pathways in NPC. Understanding these molecular interactions could remarkably impact the diagnosis, prognosis, and therapeutic strategies for NPC.
Collapse
Affiliation(s)
- Rabiatul Basria S M N Mydin
- Department of Biomedical Science, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kepala Batas, Pulau Pinang, Malaysia
- Department of Metabolism, Digestion, and Reproduction, Imperial College London, London, UK
| | - Adam Azlan
- Department of Biomedical Science, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kepala Batas, Pulau Pinang, Malaysia
- School of General and Foundation Studies, Asian Institute of Medicine, Science and Technology (AIMST University), Bedong, Kedah, Malaysia
| | - Simon I Okekpa
- Department of Biomedical Science, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kepala Batas, Pulau Pinang, Malaysia
- Department of Medical Laboratory Science, Faculty of Health Sciences, Ebonyi State University, Abakaliki, Nigeria
| | - Nigel J Gooderham
- Department of Metabolism, Digestion, and Reproduction, Imperial College London, London, UK
| |
Collapse
|
3
|
MicroRNA-384 inhibits nasopharyngeal carcinoma growth and metastasis via binding to Smad5 and suppressing the Wnt/β-catenin axis. Cytotechnology 2021; 73:203-215. [PMID: 33911345 PMCID: PMC8035371 DOI: 10.1007/s10616-021-00458-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2020] [Accepted: 02/05/2021] [Indexed: 01/10/2023] Open
Abstract
Nasopharyngeal carcinoma (NPC) is a major otorhinolaryngological disease with limited effective therapeutic options. This work focused on the function of microRNA-384 (miR-384) on the NPC pathogenesis and the molecules involved. miR-384 expression in cancer tissues and cells was detected. Gain- and loss-of-functions of miR-384 were performed to identify its role in NPC progression. The target mRNA of miR-384 was predicted on an online system and validated through a luciferase reporter assay. The activity of Wnt/β-catenin signaling was detected. Consequently, miR-384 was found to be poorly expressed in NPC tissues and cell lines and was linked to unfavorable survival rates in patients. Overexpression of miR-384 in 6-10B cells suppressed growth, migration, invasion and resistance to apoptosis of cells, but inverse trends were presented in C6661 cells where miR-384 was downregulated. miR-384 targeted Smad5 mRNA. Upregulation of Smad5 counteracted the roles of miR-384 mimic in cells. The NPC-inhibiting effects of miR-384 mimic were also blocked by Wnt/β-catenin activation. To conclude, miR-384 targets Smad5 and inactivates the Wnt/β-catenin pathway, which exerts a suppressing role in NPC cell behaviors as well as tumor growth in vivo. The findings may offer novel thoughts into NPC therapy. Supplementary Information The online version contains supplementary material available at 10.1007/s10616-021-00458-3.
Collapse
|
4
|
Yang Z, Wang J, Zhang Z, Tang F. Epstein-Barr Virus-Encoded Products Promote Circulating Tumor Cell Generation: A Novel Mechanism of Nasopharyngeal Carcinoma Metastasis. Onco Targets Ther 2019; 12:11793-11804. [PMID: 32099385 PMCID: PMC6997419 DOI: 10.2147/ott.s235948] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2019] [Accepted: 12/10/2019] [Indexed: 12/24/2022] Open
Abstract
Epstein–Barr virus (EBV) is a specific tumorigenic factor in the pathogenesis of nasopharyngeal carcinoma (NPC). Viral products encoded by EBV (LMP1, LMP2A, EBNA1, and miRNAs) have been shown to promote NPC metastasis. EBV-encoded oncoproteins and miRNAs have been shown to induce epithelial–mesenchymal transition (EMT) indirectly by inducing EMT transcription factors (EMT-TFs). These EBV-encoded products also promote the expression of EMT-TFs through post-transcriptional regulation. EMT contributes to generation of circulating tumor cells (CTCs) in epithelial cancers. CTCs exhibit stem cell characteristics, including increased invasiveness, enhanced cell intravasation, and improved cell survival in the peripheral system. EBV may contribute NPC metastasis through promoting generation of CTCs. Furthermore, CTC karyotypes are associated with NPC staging, therapeutic sensitivity, and resistance. We summarized studies showing that EBV-encoded virus-proteins and miRNAs promote generation of NPC CTCs, and highlighted the associated mechanism. This synthesis indicated that EBV mediates NPC metastasis through generation of CTCs.
Collapse
Affiliation(s)
- Zongbei Yang
- Zhuhai People's Hospital, Zhuhai Hospital of Jinan University, Zhuhai, People's Republic of China.,Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China
| | - Jing Wang
- Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China
| | - Zhenlin Zhang
- Zhuhai People's Hospital, Zhuhai Hospital of Jinan University, Zhuhai, People's Republic of China
| | - Faqing Tang
- Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China
| |
Collapse
|
5
|
Velapasamy S, Dawson CW, Young LS, Paterson IC, Yap LF. The Dynamic Roles of TGF-β Signalling in EBV-Associated Cancers. Cancers (Basel) 2018; 10:E247. [PMID: 30060514 PMCID: PMC6115974 DOI: 10.3390/cancers10080247] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2018] [Revised: 07/23/2018] [Accepted: 07/25/2018] [Indexed: 02/07/2023] Open
Abstract
The transforming growth factor-β (TGF-β) signalling pathway plays a critical role in carcinogenesis. It has a biphasic action by initially suppressing tumorigenesis but promoting tumour progression in the later stages of disease. Consequently, the functional outcome of TGF-β signalling is strongly context-dependent and is influenced by various factors including cell, tissue and cancer type. Disruption of this pathway can be caused by various means, including genetic and environmental factors. A number of human viruses have been shown to modulate TGF-β signalling during tumorigenesis. In this review, we describe how this pathway is perturbed in Epstein-Barr virus (EBV)-associated cancers and how EBV interferes with TGF-β signal transduction. The role of TGF-β in regulating the EBV life cycle in tumour cells is also discussed.
Collapse
Affiliation(s)
- Sharmila Velapasamy
- Department of Oral & Craniofacial Sciences, Faculty of Dentistry, University of Malaya, 50603 Kuala Lumpur, Malaysia.
| | - Christopher W Dawson
- Institute of Cancer and Genomic Medicine, University of Birmingham, Birmingham B15 2TT, UK.
| | - Lawrence S Young
- Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK.
| | - Ian C Paterson
- Department of Oral & Craniofacial Sciences, Faculty of Dentistry, University of Malaya, 50603 Kuala Lumpur, Malaysia.
- Oral Cancer Research and Coordinating Centre, University of Malaya, 50603 Kuala Lumpur, Malaysia.
| | - Lee Fah Yap
- Department of Oral & Craniofacial Sciences, Faculty of Dentistry, University of Malaya, 50603 Kuala Lumpur, Malaysia.
- Oral Cancer Research and Coordinating Centre, University of Malaya, 50603 Kuala Lumpur, Malaysia.
| |
Collapse
|
6
|
Deng C, Lin YX, Qi XK, He GP, Zhang Y, Zhang HJ, Xu M, Feng QS, Bei JX, Zeng YX, Feng L. TNFRSF19 Inhibits TGFβ Signaling through Interaction with TGFβ Receptor Type I to Promote Tumorigenesis. Cancer Res 2018; 78:3469-3483. [PMID: 29735548 DOI: 10.1158/0008-5472.can-17-3205] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2017] [Revised: 03/27/2018] [Accepted: 04/26/2018] [Indexed: 11/16/2022]
Abstract
Genetic susceptibility underlies the pathogenesis of cancer. We and others have previously identified a novel susceptibility gene TNFRSF19, which encodes an orphan member of the TNF receptor superfamily known to be associated with nasopharyngeal carcinoma (NPC) and lung cancer risk. Here, we show that TNFRSF19 is highly expressed in NPC and is required for cell proliferation and NPC development. However, unlike most of the TNF receptors, TNFRSF19 was not involved in NFκB activation or associated with TRAF proteins. We identified TGFβ receptor type I (TβRI) as a specific binding partner for TNFRSF19. TNFRSF19 bound the kinase domain of TβRI in the cytoplasm, thereby blocking Smad2/3 association with TβRI and subsequent signal transduction. Ectopic expression of TNFRSF19 in normal epithelial cells conferred resistance to the cell-cycle block induced by TGFβ, whereas knockout of TNFRSF19 in NPC cells unleashed a potent TGFβ response characterized by upregulation of Smad2/3 phosphorylation and TGFβ target gene transcription. Furthermore, elevated TNFRSF19 expression correlated with reduced TGFβ activity and poor prognosis in patients with NPC. Our data reveal that gain of function of TNFRSF19 in NPC represents a mechanism by which tumor cells evade the growth-inhibitory action of TGFβ.Significance:TNFRSF19, a susceptibility gene for nasopharyngeal carcinoma and other cancers, functions as a potent inhibitor of the TGFβ signaling pathway.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/13/3469/F1.large.jpg Cancer Res; 78(13); 3469-83. ©2018 AACR.
Collapse
Affiliation(s)
- Chengcheng Deng
- Department of Experimental Research, Sun Yat-sen University Cancer Center, State Key Laboratory Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Yu-Xin Lin
- Department of Experimental Research, Sun Yat-sen University Cancer Center, State Key Laboratory Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Xue-Kang Qi
- Department of Experimental Research, Sun Yat-sen University Cancer Center, State Key Laboratory Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Gui-Ping He
- Department of Experimental Research, Sun Yat-sen University Cancer Center, State Key Laboratory Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Yuchen Zhang
- Department of Experimental Research, Sun Yat-sen University Cancer Center, State Key Laboratory Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Hao-Jiong Zhang
- Department of Experimental Research, Sun Yat-sen University Cancer Center, State Key Laboratory Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Miao Xu
- Department of Experimental Research, Sun Yat-sen University Cancer Center, State Key Laboratory Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Qi-Sheng Feng
- Department of Experimental Research, Sun Yat-sen University Cancer Center, State Key Laboratory Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Jin-Xin Bei
- Department of Experimental Research, Sun Yat-sen University Cancer Center, State Key Laboratory Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Yi-Xin Zeng
- Department of Experimental Research, Sun Yat-sen University Cancer Center, State Key Laboratory Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
| | - Lin Feng
- Department of Experimental Research, Sun Yat-sen University Cancer Center, State Key Laboratory Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
| |
Collapse
|
7
|
Du M, Chen W, Zhang W, Tian XK, Wang T, Wu J, Gu J, Zhang N, Lu ZW, Qian LX, Fei Q, Wang Y, Peng F, He X, Yin L. TGF-? regulates the ERK/MAPK pathway independent of the SMAD pathway by repressing miRNA-124 to increase MALAT1 expression in nasopharyngeal carcinoma. Biomed Pharmacother 2018; 99:688-696. [PMID: 29710466 DOI: 10.1016/j.biopha.2018.01.120] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2017] [Revised: 01/13/2018] [Accepted: 01/24/2018] [Indexed: 12/12/2022] Open
Abstract
Transforming growth factor beta (TGF-?), a pleiotropic cytokine, promotes cell proliferation and migration in multiple cancers, including nasopharyngeal carcinoma (NPC). microRNA-124 (miR-124) becomes downregulated in NPC and inhibits the tumorigenesis of this disease. However, the role of miR-124 in TGF-?-induced NPC development remains unknown. In this study, constant TGF-? stimulation repressed miR-124 expression, whereas miR-124 overexpression antagonized TGF-?-promoted NPC cell growth and migration. miR-124 overexpression decreased p-SMAD2/3, SMAD4, and p-ERK levels, indicating that ectopic miR-124 overexpression inhibited SMAD and non-SMAD pathways. Pro-oncogenic lncRNA MALAT1 was targeted by miR-124 that regulated ERK/MAPK by targeting MALAT1 independent of the SMAD signaling pathway. In conclusion, our work clarified the significant role of miR-124 in TGF-? signaling pathways independent of the SMAD signaling pathway and showed the potential of miR-124 as a new therapeutic target against NPC.
Collapse
Affiliation(s)
- Mingyu Du
- Jiangsu Cancer Hospital & Jiangsu Institue of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital, 42 Bai Zi Ting Road, Nanjing, Jiangsu 210000, China; Xuzhou Medical University, 209 Tong-Shan Road, Xuzhou, Jiangsu, China
| | - Wei Chen
- Jiangsu Cancer Hospital & Jiangsu Institue of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital, 42 Bai Zi Ting Road, Nanjing, Jiangsu 210000, China
| | - Wenjun Zhang
- Jiangsu Cancer Hospital & Jiangsu Institue of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital, 42 Bai Zi Ting Road, Nanjing, Jiangsu 210000, China
| | - Xiao-Kang Tian
- Xuzhou Medical University, 209 Tong-Shan Road, Xuzhou, Jiangsu, China
| | - Tingting Wang
- Jiangsu Cancer Hospital & Jiangsu Institue of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital, 42 Bai Zi Ting Road, Nanjing, Jiangsu 210000, China
| | - Jing Wu
- Jiangsu Cancer Hospital & Jiangsu Institue of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital, 42 Bai Zi Ting Road, Nanjing, Jiangsu 210000, China
| | - Jiajia Gu
- Jiangsu Cancer Hospital & Jiangsu Institue of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital, 42 Bai Zi Ting Road, Nanjing, Jiangsu 210000, China
| | - Nan Zhang
- Jiangsu Cancer Hospital & Jiangsu Institue of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital, 42 Bai Zi Ting Road, Nanjing, Jiangsu 210000, China
| | - Zhi-Wei Lu
- The Fourth Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu, China
| | - Lu-Xi Qian
- The Fourth Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu, China
| | - Qian Fei
- The Fourth Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu, China
| | - Yan Wang
- The Fourth Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu, China
| | - Fanyu Peng
- The Fourth Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu, China
| | - Xia He
- Jiangsu Cancer Hospital & Jiangsu Institue of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital, 42 Bai Zi Ting Road, Nanjing, Jiangsu 210000, China; Xuzhou Medical University, 209 Tong-Shan Road, Xuzhou, Jiangsu, China.
| | - Li Yin
- Jiangsu Cancer Hospital & Jiangsu Institue of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital, 42 Bai Zi Ting Road, Nanjing, Jiangsu 210000, China.
| |
Collapse
|
8
|
Wang Y, Zhao Q, Lan N, Wang S. Identification of methylated genes and miRNA signatures in nasopharyngeal carcinoma by bioinformatics analysis. Mol Med Rep 2018; 17:4909-4916. [PMID: 29393436 PMCID: PMC5865950 DOI: 10.3892/mmr.2018.8487] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2017] [Accepted: 06/13/2017] [Indexed: 12/11/2022] Open
Abstract
Nasopharyngeal carcinoma (NPC) is prevalent in several regions, including. Southern China and Southeast Asia, with high mortality. The present study aimed to explore the epigenetic mechanisms of NPC and to provide novel biomarkers for prognosis. Two methylation data sets (GSE52068 and GSE62336) were downloaded from the Gene Expression Omnibus database. Following pretreatment of the raw data, differentially methylated regions (DMRs) and differentially methylated CpG islands (DMCs) were identified between the NPC samples and normal tissue controls using COHCAP software. The overlapped DMRs and DMCs in the two data sets were extracted and associated to relevant genes. Enrichment analysis and protein-protein interaction (PPI) network analyses were performed on the identified genes using Database for Annotation, Visualization and Integration Discovery and Cytoscape, respectively. MicroRNAs (miRNAs) targeting the overlapped genes were identified based on the miRWalk database. NPC-related genes were analyzed with the Comparative Toxicogenomics Database. Multiple overlapping DMRs between the two data sets were identified and were associated with 1,854 hypermethylated and 18 hypomethylated genes, which were revealed to be enriched in certain pathways, including the mitogen-activated protein kinase (MAPK) signaling pathway and the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway. Several nodes in the predicted PPI network were highlighted, including proto-oncogene tyrosine-protein kinase SRC, SMAD family member 3 (SMAD3), tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein ζ (YWHAZ) and Heat shock protein family A member 4 (HSPA4), all of which were hypomethylated. A total of 14 miRNAs were identified that correlated with the overlapped genes such as miRNA (miR)-148a-3p, which was predicted to target of HSPA4; and 17 genes were identified as related to NPC, including SMAD3 and SRC. miR129-2 was hypermethylated. Several novel methylated genes or miRNAs were suggested as biomarkers for NPC prognosis: Hypomethylation of SRC, SMAD3, YWHAZ and HSPA4, and hypermethylation of miR129-2 may be linked to poor prognosis of NPC.
Collapse
Affiliation(s)
- Yingli Wang
- Department of Otorhinolaryngology, Cangzhou People's Hospital, Cangzhou, Hebei 061000, P.R. China
| | - Qun Zhao
- Department of Otorhinolaryngology, Cangzhou Central Hospital, Cangzhou, Hebei 061000, P.R. China
| | - Na Lan
- Department of Otorhinolaryngology, Cangzhou People's Hospital, Cangzhou, Hebei 061000, P.R. China
| | - Shuqian Wang
- Department of Otorhinolaryngology, Cangzhou People's Hospital, Cangzhou, Hebei 061000, P.R. China
| |
Collapse
|
9
|
Wang W, Yi M, Chen S, Li J, Li G, Yang J, Zheng P, Zhang H, Xiong W, McCarthy JB, Li G, Li X, Xiang B. Significance of the NOR1-FOXA1/HDAC2-Slug regulatory network in epithelial-mesenchymal transition of tumor cells. Oncotarget 2017; 7:16745-59. [PMID: 26934447 PMCID: PMC4941348 DOI: 10.18632/oncotarget.7778] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2015] [Accepted: 01/01/2016] [Indexed: 12/16/2022] Open
Abstract
The epithelial-mesenchymal transition (EMT) process is believed to play a crucial role in nasopharyngeal carcinoma (NPC) progression, a squamous cell carcinoma of the head and neck with the tendency to metastasize early. At present, much attention has been given to the inducer of EMT involved in NPC progression, while antagonists have been less intensively characterized. In this study, unbiased analysis of EMT-associated gene expression patterns was performed using data mining of global gene expression profiles derived from NPC samples, leading to the successful identification of NOR1, FOXA1, and Slug, all of which showed aberrant expression during NPC progression. The effect of tumor suppressor NOR1 on Slug-induced NPC cells during the EMT process was investigated by use of ectopic expression and RNA interference methods. The molecular mechanisms underlying the tumor-suppressing effect of NOR1 on Slug-induced EMT were thought to be dependent on the cooperation of NOR1 with the FOXA1-HDAC2 complex. We also showed that FOXA1 and HDAC2 bind the slug promoter and directly repress its transcription. Our data revealed a previously unrecognized role of the NOR1-FOXA1/HDAC2-Slug network in the regulation of the EMT process and aggressiveness of NPC.
Collapse
Affiliation(s)
- Wei Wang
- Hunan Provincial Cancer Hospital and Cancer Hospital Affiliated to Xiangya Medical School, The Central South University, Changsha, Hunan 410013, China.,Cancer Research Institute, Xiangya School of Medicine, The Central South University, Changsha 410078, China.,Department of Pathology, Affiliated Hospital of Jining Medical University, Jining, 272029, Shandong, China
| | - Mei Yi
- Department of Dermatology, Xiangya Hospital, The Central South University, Changsha, 410008, Hunan, China
| | - Shengnan Chen
- Hunan Provincial Cancer Hospital and Cancer Hospital Affiliated to Xiangya Medical School, The Central South University, Changsha, Hunan 410013, China.,Cancer Research Institute, Xiangya School of Medicine, The Central South University, Changsha 410078, China
| | - Junjun Li
- Cancer Research Institute, Xiangya School of Medicine, The Central South University, Changsha 410078, China
| | - Guo Li
- Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, The Central South University, Changsha, 410008, Hunan, China
| | - Jianbo Yang
- Department of Laboratory Medicine and Pathology, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - Pan Zheng
- Cancer Research Institute, Xiangya School of Medicine, The Central South University, Changsha 410078, China
| | - Haijing Zhang
- Cancer Research Institute, Xiangya School of Medicine, The Central South University, Changsha 410078, China
| | - Wei Xiong
- Cancer Research Institute, Xiangya School of Medicine, The Central South University, Changsha 410078, China
| | - James B McCarthy
- Department of Laboratory Medicine and Pathology, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - Guiyuan Li
- Cancer Research Institute, Xiangya School of Medicine, The Central South University, Changsha 410078, China
| | - Xiaoling Li
- Cancer Research Institute, Xiangya School of Medicine, The Central South University, Changsha 410078, China
| | - Bo Xiang
- Hunan Provincial Cancer Hospital and Cancer Hospital Affiliated to Xiangya Medical School, The Central South University, Changsha, Hunan 410013, China.,Cancer Research Institute, Xiangya School of Medicine, The Central South University, Changsha 410078, China
| |
Collapse
|
10
|
Guo C, Ma J, Deng G, Qu Y, Yin L, Li Y, Han Y, Cai C, Shen H, Zeng S. ZEB1 Promotes Oxaliplatin Resistance through the Induction of Epithelial - Mesenchymal Transition in Colon Cancer Cells. J Cancer 2017; 8:3555-3566. [PMID: 29151941 PMCID: PMC5687171 DOI: 10.7150/jca.20952] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2017] [Accepted: 09/01/2017] [Indexed: 02/07/2023] Open
Abstract
Background: Oxaliplatin (OXA) chemotherapy is widely used in the clinical treatment of colon cancer. However, chemo-resistance is still a barrier to effective chemotherapy in cases of colon cancer. Accumulated evidence suggests that the epithelial mesenchymal transition (EMT) may be a critical factor in chemo-sensitivity. The present study investigated the effects of Zinc finger E-box binding homeobox 1 (ZEB1) on OXA-sensitivity in colon cancer cells. Method: ZEB1expression and its correlation with clinicopathological characteristics were analyzed using tumor tissue from an independent cohort consisting of 118 colon cancer (CC) patients who receiving OXA-based chemotherapy. ZEB1 modulation of OXA-sensitivity in colon cancer cells was investigated in a OXA-resistant subline of HCT116/OXA cells and the parental colon cancer cell line: HCT116. A CCK8 assay was carried out to determine OXA-sensitivity. qRT-PCR, Western blot, Scratch wound healing and transwell assays were used to determine EMT phenotype of colon cells. ZEB1 knockdown using small interfering RNA (siRNA) was used to determine the ZEB1 contribution to OXA-sensitivity in vitro and in vivo (in a nude mice xenograft model). Result: ZEB1 expression was significantly increased in colon tumor tissue, and was correlated with lymph node metastasis and the depth of invasion. Compared with the parental colon cancer cells (HCT116), HCT116/OXA cells exhibited an EMT phenotype characterized by up-regulated expression of ZEB1, Vimentin, MMP2 and MMP9, but down-regulated expression of E-cadherin. Transfection of Si-ZEB1 into HCT116/OXA cells significantly reversed the EMT phenotype and enhanced OXA-sensitivity in vitro and in vivo. Conclusion: HCT116/OXA cells acquired an EMT phenotype. ZEB1 knockdown effectively restored OXA-sensitivity by reversing EMT. ZEB1 is a potential therapeutic target for the prevention of OXA-resistance in colon cancer.
Collapse
Affiliation(s)
- Cao Guo
- Institute of Medical Sciences, Xiangya Hospital, Central South University, Changsha, Hunan, China 410008.,Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, Hunan, China 410008
| | - Junli Ma
- Institute of Medical Sciences, Xiangya Hospital, Central South University, Changsha, Hunan, China 410008.,Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China 410008
| | - Ganlu Deng
- Institute of Medical Sciences, Xiangya Hospital, Central South University, Changsha, Hunan, China 410008.,Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China 410008
| | - Yanlin Qu
- Institute of Medical Sciences, Xiangya Hospital, Central South University, Changsha, Hunan, China 410008.,Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China 410008
| | - Ling Yin
- Institute of Medical Sciences, Xiangya Hospital, Central South University, Changsha, Hunan, China 410008.,Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China 410008
| | - Yiyi Li
- Institute of Medical Sciences, Xiangya Hospital, Central South University, Changsha, Hunan, China 410008.,Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China 410008
| | - Ying Han
- Institute of Medical Sciences, Xiangya Hospital, Central South University, Changsha, Hunan, China 410008.,Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China 410008
| | - Changjing Cai
- Institute of Medical Sciences, Xiangya Hospital, Central South University, Changsha, Hunan, China 410008.,Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China 410008
| | - Hong Shen
- Institute of Medical Sciences, Xiangya Hospital, Central South University, Changsha, Hunan, China 410008.,Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, Hunan, China 410008.,Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China 410008
| | - Shan Zeng
- Institute of Medical Sciences, Xiangya Hospital, Central South University, Changsha, Hunan, China 410008.,Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, Hunan, China 410008.,Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China 410008
| |
Collapse
|
11
|
Liao ZW, Zhao L, Cai MY, Xi M, He LR, Yu F, Zhou TC, Liu MZ. P300 promotes migration, invasion and epithelial-mesenchymal transition in a nasopharyngeal carcinoma cell line. Oncol Lett 2016; 13:763-769. [PMID: 28356956 PMCID: PMC5351396 DOI: 10.3892/ol.2016.5491] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2015] [Accepted: 10/27/2016] [Indexed: 11/15/2022] Open
Abstract
A previous study demonstrated that p300 is overexpressed in nasopharyngeal carcinoma (NPC), and that its expression is an independent prognostic factor. The aim of the present study is to investigate the role of p300 in human NPC development. A small hairpin (sh) RNA lentiviral expression vector targeting the p300 gene was constructed to suppress the expression of p300 in NPC cells. Knockdown of p300 was verified by reverse transcription-quantitative polymerase chain reaction and western blotting. Wound-healing, invasion, immunofluorescence and immunoprecipitation assays were performed to assess the influence of p300 on nasopharyngeal tumorigenesis and metastasis in vitro. The expression of p300 was upregulated in NPC cell lines. After knockdown of p300, the migration and invasion ability of shp300 cells were significantly inhibited (P<0.05). Furthermore, the depletion of p300 expression in NPC cell lines resulted in the upregulation of epithelial phenotype marker E-cadherin and α-catenin, and downregulation of mesenchymal phenotype markers N-cadherin and vimentin. p300 promotes epithelial-mesenchymal transition (EMT) through the acetylation of Smad2 and Smad3 in the tumor growth factor-β signaling pathway. In conclusion, p300 may be involved in the invasion and metastasis of NPC through the induction of EMT.
Collapse
Affiliation(s)
- Zhi-Wei Liao
- Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China; Department of Radiation Oncology, The Tumour Hospital Affiliated of Guangzhou Medical University, Guangzhou, Guangdong 510095, P.R. China
| | - Lei Zhao
- Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China
| | - Mu-Yan Cai
- Department of Pathology, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China
| | - Mian Xi
- Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China
| | - Li-Ru He
- Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China
| | - Fang Yu
- Department of Radiation Oncology, The Tumour Hospital Affiliated of Guangzhou Medical University, Guangzhou, Guangdong 510095, P.R. China
| | - Tong-Chong Zhou
- Department of Radiation Oncology, The Tumour Hospital Affiliated of Guangzhou Medical University, Guangzhou, Guangdong 510095, P.R. China
| | - Meng-Zhong Liu
- Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China
| |
Collapse
|
12
|
miR-145 inhibits invasion and metastasis by directly targeting Smad3 in nasopharyngeal cancer. Tumour Biol 2015; 36:4123-31. [PMID: 25578496 DOI: 10.1007/s13277-015-3046-6] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2014] [Accepted: 01/02/2015] [Indexed: 12/31/2022] Open
Abstract
MicroRNA-145 (miR-145) has been implicated in several cancers. However, its role in nasopharyngeal carcinoma (NPC) remains unclear. In this study, we proved that miR-145 was significantly downregulated in NPC and associated with NPC cell metastasis. Moreover, miR-145 suppressed Smad3 by directly binding to the 3'-untranslated region (UTR) of Smad3. Knockdown of Smad3 in NPC cells inhibited cell migration and invasion, which was consistent with the effect of miR-145 in NPC cells. In addition, Smad3 expression was inversely correlated with miR-145 level in clinical NPC samples. Taken together, our findings indicate that miR-145 is a tumour suppressor that affects invasive and metastatic properties of NPC via the miR-145/Smad3 axis, leading us to propose that miR-145 overexpression might be a potential therapeutic strategy of NPC intervention.
Collapse
|
13
|
Limb-bud and Heart (LBH) functions as a tumor suppressor of nasopharyngeal carcinoma by inducing G1/S cell cycle arrest. Sci Rep 2015; 5:7626. [PMID: 25557837 PMCID: PMC4283826 DOI: 10.1038/srep07626] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2014] [Accepted: 12/04/2014] [Indexed: 12/18/2022] Open
Abstract
Epstein–Barr virus-encoded latent membrane protein-1 (LMP1) plays a fundamental role in the
malignant transformation of nasopharyngeal carcinoma (NPC), although the mechanism is not well
understood. Here, we showed that Limb-bud and Heart (LBH) is considerably downregulated in patient
NPC tissues. The expression of LBH in biopsies of 40 consecutive NPC patients devoid of initial
distant metastasis and treated according to consistent guidelines was also analyzed, and we found
the LBH expression level was correlated with some of clinicopathological features, disease-specific
survival (DSS), distant metastasis-free survival (DMFS). We further determined that LBH normally
induces NPC cell cycle arrest at the G1/S transition, and LBH can suppress the growth of
transplanted NPC tumors in vivo by downregulating LMP1-mediated NF-κB transcriptional activity.
Transforming growth factor-beta 1 (TGF-β1) normally protects against tumor development by
suppressing cell proliferation, but NPC cells acquire resistance to TGF-β1–mediated
inhibition. We found that TGF-β1 inhibits NF-κB transcriptional activity and nasopharyngeal
epithelial cell proliferation through upregulating LBH expression. These data reveal a previously
unknown NPC transformation mechanism and provide a new concept and treatment strategy for
LMP1-driven oncogenesis in NPC.
Collapse
|
14
|
Li Y, Gong W, Ma X, Sun X, Jiang H, Chen T. Smad7 maintains epithelial phenotype of ovarian cancer stem-like cells and supports tumor colonization by mesenchymal-epithelial transition. Mol Med Rep 2014; 11:309-16. [PMID: 25333457 DOI: 10.3892/mmr.2014.2714] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2014] [Accepted: 08/07/2014] [Indexed: 11/06/2022] Open
Abstract
Epithelial ovarian carcinoma (EOC) is a lethal gynecological malignancy. Epithelial-mesenchymal transition (EMT) has an important role in the tumorigenesis and progression of EOC. During the process of EMT, the transforming growth factor-β (TGF-β)-Smad signaling pathway has been indicated to regulate cell motility and tumor development. Among numerous EMT-associated transcripts, Smad7 is considered to be an inhibitor, however its involvement together with TGF-β1 in the progression of ovarian cancer remains to be elucidated. The present study demonstrated that Smad7 was overexpressed in SK-OV-3 and stem-like side populations of EOC cells, both of which grow in an epithelial pattern. The transformation of cells from an epithelial to a mesenchymal phenotype was stimulated by TGF-β1 with a corresponding increase in Smad7 expression in SK-OV-3 cells. These results indicate that Smad7 is a regulator in the maintenance of the epithelial phenotype in EOC cells, and may serve as an inhibitory element which targets TGF-β-stimulated EMT. Furthermore, inhibition of Smad7 resulted in cellular mesenchymal transformation, with an increased expression of N-cadherin and a decreased expression of E-cadherin. The invasiveness and migratory capabilities of Smad7 small hairpin RNA transduced EOC cells was also reduced. The findings of the present study have identified Smad7 as a fundamental factor in the maintenance of epithelial growth of EOC cells. Reversal of EMT results in a mesenchymal-epithelial transition, which is necessary for EOC cell colonization at metastatic sites.
Collapse
Affiliation(s)
- Yiying Li
- Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China
| | - Wenjia Gong
- Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China
| | - Xiaoling Ma
- Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China
| | - Xiaoxi Sun
- Shanghai Ji Ai Genetics and IVF Institute, Shanghai 200011, P.R. China
| | - Hua Jiang
- Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China
| | - Tong Chen
- Department of Hematology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China
| |
Collapse
|